A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Karn, Thomas; Meissner, Tobias; Weber, Karsten E.; Solbach, Christine; Denkert, Carsten; Engels, Knut; Fasching, Peter A.; Sinn, Bruno V.; Schrader, Iris; Budczies, Jan; Marme, Frederik; Mueller, Volkmar; Holtrich, Uwe; Gerber, Bernd; Schem, Christian; Young, Brandon M.; Hanusch, Claus; Stickeler, Elmar; Huober, Jens; van Mackelenbergh, Marion; Leyland-Jones, Brian; Fehm, Tanja; Nekljudova, Valentina; Untch, Michael; Loibl, Sibylle

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Autor(en):

Karn, Thomas; Meissner, Tobias; Weber, Karsten E.; Solbach, Christine; Denkert, Carsten; Engels, Knut; Fasching, Peter A.; Sinn, Bruno V.; Schrader, Iris; Budczies, Jan; Marme, Frederik; Mueller, Volkmar; Holtrich, Uwe; Gerber, Bernd; Schem, Christian; Young, Brandon M.; Hanusch, Claus; Stickeler, Elmar; Huober, Jens; van Mackelenbergh, Marion; Leyland-Jones, Brian; Fehm, Tanja; Nekljudova, Valentina; Untch, Michael; Loibl, Sibylle

Tübinger Autor(en):

Fehm, Tanja

Erschienen in:

Clinical Cancer Research (2020), Bd. 26, H. 8, S. 1896-1904

Verlagsangabe:

Amer Assoc Cancer Research

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1158/1078-0432.CCR-19-1954

ISSN:

1557-3265